





Item 8.01

Other Events.

On September 28, 2017, VistaGen Therapeutics, Inc. (the “Company”) announced its receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 14/775,287 related to certain methods of production for AV-101, the Company’s lead product candidate for the treatment of Major Depressive Disorder and certain other diseases and disorders of the central nervous system. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01

Exhibits.

See Exhibit Index.



Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: October 2, 2017 By: /s/ Shawn K. Singh  
Shawn K. Singh  
Chief Executive Officer



EXHIBIT INDEX

Exhibit Number Description

99.1 Press release issued by VistaGen Therapeutics, Inc., dated September 28, 2017.